|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jin J, Cai L, Liu ZM and Zhou XS:
miRNA-218 inhibits osteosarcoma cell migration and invasion by
down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev.
14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Han K, Chen X, Bian N, Ma B, Yang T, Cai
C, Fan Q, Zhou Y and Zhao TB: MicroRNA profiling identifies MiR-195
suppresses osteosarcoma cell metastasis by targeting CCND1.
Oncotarget. 6:8875–8889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: where do we go from here? Paediatr Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyers PA, Heller G, Healey J, Huvos A,
Lane J, Marcove R, Applewhite A, Vlamis V and Rosen G: Chemotherapy
for nonmetastatic osteogenic sarcoma: The memorial sloan-kettering
experience. J Clin Oncol. 10:5–15. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lv H, Guo J, Li S and Jiang D: inhibitor
reduces the proliferation and migration in osteosarcoma MG-63
cells. Exp Ther Med. 8:1575–1580. 2014.PubMed/NCBI
|
|
7
|
PosthumaDeBoer J, Witlox MA, Kaspers GJ
and van Royen BJ: Molecular alterations as target for therapy in
metastatic osteosarcoma: A review of literature. Clin Exp
Metastasis. 28:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Diao CY, Guo HB, Ouyang YR, Zhang HC, Liu
LH, Bu J, Wang ZH and Xiao T: Screening for metastatic osteosarcoma
biomarkers with a DNA microarray. Asian Pac J Cancer Prev.
15:1817–1822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bentwich I, Avniel A, Karov Y, Aharonov R,
Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al:
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: MicroRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu W, Zhao ZY, Shi L and Yuan WD: Tissue
microRNA-126 expression level predicts outcome in human
osteosarcoma. Diagn Pathol. 10:1162015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tahara H, Kay MA, Yasui W and Tahara E:
MicroRNAs in Cancer: The 22nd Hiroshima Cancer Seminar/the 4th
Japanese Association for RNA Interference Joint International
Symposium, 30 August 2012, Grand Prince hotel Hiroshima. Jpn J Clin
Oncol. 43:579–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang F, Ren X and Zhang X: Role of
microRNA-150 in solid tumors. Oncol Lett. 10:11–16. 2015.PubMed/NCBI
|
|
20
|
Weiland M, Gao XH, Zhou L and Mi QS: Small
RNAs have a large impact: Circulating microRNAs as biomarkers for
human diseases. RNA Biol. 9:850–859. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Srivastava SK, Bhardwaj A, Singh S, Arora
S, Wang B, Grizzle WE and Singh AP: MicroRNA-150 directly targets
MUC4 and suppresses growth and malignant behavior of pancreatic
cancer cells. Carcinogenesis. 32:1832–1839. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yokobori T, Suzuki S, Tanaka N, Inose T,
Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H and Kuwano
H: MiR-150 is associated with poor prognosis in esophageal squamous
cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci.
104:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pizzini S, Bisognin A, Mandruzzato S,
Biasiolo M, Facciolli A, Perilli L, Rossi E, Esposito G, Rugge M,
Pilati P, et al: Impact of microRNAs on regulatory networks and
pathways in human colorectal carcinogenesis and development of
metastasis. BMC Genomics. 14:5892013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu F, Lu Z, Chen B, Dong P and Zheng J:
microRNA-150: A promising novel biomarker for hepatitis B
virus-related hepatocellular carcinoma. Diagn Pathol. 10:1292015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin M, Yang Z, Ye W, Xu H and Hua X:
MicroRNA-150 predicts a favorable prognosis in patients with
epithelial ovarian cancer, and inhibits cell invasion and
metastasis by suppressing transcriptional repressor ZEB1. PLoS One.
9:e1039652014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Watanabe A, Tagawa H, Yamashita J, Teshima
K, Nara M, Iwamoto K, Kume M, Kameoka Y, Takahashi N, Nakagawa T,
et al: The role of microRNA-150 as a tumor suppressor in malignant
lymphoma. Leukemia. 25:1324–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dezhong L, Xiaoyi Z, Xianlian L, Hongyan
Z, Guohua Z, Bo S, Shenglei Z and Lian Z: miR-150 is a factor of
survival in prostate cancer patients. J BUON. 20:173–179.
2015.PubMed/NCBI
|
|
29
|
Gu XY, Wang J, Luo YZ, Du Q, Li RR, Shi H
and Yu TP: Down-regulation of miR-150 induces cell proliferation
inhibition and apoptosis in non-small-cell lung cancer by targeting
BAK1 in vitro. Tumour Biol. 35:5287–5293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang S, Chen Y, Wu W, Ouyang N, Chen J,
Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast
cancer growth and malignant behavior by targeting the pro-apoptotic
purinergic P2X7 receptor. PLoS One. 8:e807072013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K,
Ren G, Su T, Pan Y, Feng B, et al: MiR-150 promotes gastric cancer
proliferation by negatively regulating the pro-apoptotic gene EGR2.
Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang K, He M, Cai Z, Ni C, Deng J, Ta N,
Xu J and Zheng J: A decrease in miR-150 regulates the malignancy of
pancreatic cancer by targeting c-Myb and MUC4. Pancreas.
44:370–379. 2015.PubMed/NCBI
|
|
33
|
Ma Y, Zhang P, Wang F, Zhang H, Yang J,
Peng J, Liu W and Qin H: miR-150 as a potential biomarker
associated with prognosis and therapeutic outcome in colorectal
cancer. Gut. 61:1447–1453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feng J, Yang Y, Zhang P, Wang F, Ma Y, Qin
H and Wang Y: miR-150 functions as a tumour suppressor in human
colorectal cancer by targeting c-Myb. J Cell Mol Med. 18:2125–2134.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang N, Wei X and Xu L: miR-150 promotes
the proliferation of lung cancer cells by targeting P53. FEBS Lett.
587:2346–2351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yin QW, Sun XF, Yang GT, Li XB, Wu MS and
Zhao J: Increased expression of microRNA-150 is associated with
poor prognosis in non-small cell lung cancer. Int J Clin Exp
Pathol. 8:842–846. 2015.PubMed/NCBI
|
|
37
|
Cao M, Hou D, Liang H, Gong F, Wang Y, Yan
X, Jiang X, Wang C, Zhang J, Zen K, et al: miR-150 promotes the
proliferation and migration of lung cancer cells by targeting SRC
kinase signalling inhibitor 1. Eur J Cancer. 50:1013–1024. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen A, Zhang Y, Yang H, Xu R and Huang G:
Overexpression of ZEB1 relates to metastasis and invasion in
osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Yan S, Liu X, Zhang W, Li Y, Dong
R, Zhang Q, Yang Q, Yuan C, Shen K and Kong B: miR-1236-3p
represses the cell migration and invasion abilities by targeting
ZEB1 in high-grade serous ovarian carcinoma. Oncol Rep.
31:1905–1910. 2014.PubMed/NCBI
|
